Hospital
Insight Chicago, INC.
Insight Chicago, INC. was paid $2.03M by Medicaid between Jan 2018 and Jul 2020, across 125 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 46% of everything it billed.
33Billing provider infoINSIGHT CHICAGO, INC.
CHICAGO, IL 60616
CHICAGO, IL 60616
33aNPI1730166224assigned 12/27/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.03M
24GClaims166,725
24DCodes billed125
24AFirst – last monthJan 2018 – Jul 2020
Compared with peers
Next to other General Acute Care Hospital providers in Illinois
Rank by total paid#21 of 129
Median peer was paid$547K
This provider vs. median3.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 62,691 | $964K | |
| 2019 | 77,079 | $835K | |
| 2020 | 26,955 | $232K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 46% | 9,632 | 2,387 | $932K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 9.8% | 3,489 | 3,322 | $198K |
| 97161 | 6.6% | 1,424 | 975 | $133K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.2% | 6,315 | 5,540 | $85K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.1% | 6,320 | 5,540 | $82K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 4.0% | 3,584 | 3,194 | $82K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.1% | 6,812 | 6,291 | $42K |
| 80053 | Comprehensive metabolic panel | 1.7% | 11,186 | 9,724 | $34K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.5% | 937 | 602 | $31K |
| 87536 | 1.2% | 574 | 528 | $23K | |
| 83655 | 1.0% | 3,880 | 3,225 | $21K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,868 | 1,660 | $20K |
113 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,805 | $16K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 585 | $14K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 723 | $13K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,464 | $13K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,337 | $12K |
| 86480 | <1% | 557 | $12K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,505 | $12K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,443 | $11K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 65 | $11K |
| 80061 | Lipid panel | <1% | 7,601 | $10K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 2,213 | $10K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 884 | $10K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,073 | $9K |
| 85027 | <1% | 7,814 | $9K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,659 | $8K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 172 | $8K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 322 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,747 | $8K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,677 | $7K |
| 97162 | <1% | 68 | $7K | |
| 92557 | <1% | 172 | $7K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 277 | $6K |
| 86003 | <1% | 479 | $5K | |
| 87340 | <1% | 1,824 | $5K | |
| 87186 | <1% | 1,233 | $5K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 310 | $5K |
| 77066 | Tomosynthesis, mammo | <1% | 56 | $4K |
| 72110 | <1% | 236 | $4K | |
| 92567 | <1% | 264 | $4K | |
| 81511 | <1% | 110 | $4K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 90 | $3K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 69 | $3K |
| 86780 | <1% | 847 | $3K | |
| 80076 | <1% | 1,063 | $3K | |
| 73562 | <1% | 317 | $3K | |
| 86706 | <1% | 830 | $3K | |
| 73030 | <1% | 287 | $3K | |
| 81001 | <1% | 3,557 | $3K | |
| 87070 | <1% | 1,738 | $3K | |
| 73564 | <1% | 156 | $2K | |
| 84439 | <1% | 1,462 | $2K | |
| 85610 | <1% | 1,891 | $2K | |
| 87081 | <1% | 906 | $2K | |
| 87517 | <1% | 78 | $2K | |
| 82274 | <1% | 442 | $2K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 265 | $2K |
| 81025 | <1% | 2,289 | $2K | |
| 86803 | <1% | 460 | $2K | |
| 83735 | <1% | 1,117 | $2K | |
| 84702 | <1% | 556 | $2K | |
| 82607 | <1% | 564 | $2K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 139 | $2K |
| 86592 | <1% | 2,191 | $2K | |
| 82105 | <1% | 263 | $2K | |
| 86762 | <1% | 1,098 | $2K | |
| 84153 | <1% | 360 | $2K | |
| 85018 | <1% | 3,977 | $1K | |
| 85014 | <1% | 3,976 | $1K | |
| 83021 | <1% | 308 | $1K | |
| 82043 | <1% | 1,597 | $1K | |
| 87205 | <1% | 1,867 | $1K | |
| 87210 | <1% | 1,759 | $1K | |
| 73130 | <1% | 130 | $1K | |
| 82950 | <1% | 854 | $1K | |
| 86850 | <1% | 1,084 | $1K | |
| 86360 | <1% | 505 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 42 | $989.04 |
| 73610 | <1% | 63 | $979.46 | |
| 85651 | <1% | 1,098 | $928.50 | |
| 86901 | <1% | 1,138 | $920.87 | |
| 77065 | Tomosynthesis, mammo | <1% | 16 | $880.61 |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 60 | $876.57 |
| 86359 | <1% | 505 | $832.46 | |
| 73630 | <1% | 80 | $831.40 | |
| 86038 | <1% | 183 | $822.52 | |
| 84481 | <1% | 393 | $814.27 | |
| 87147 | <1% | 853 | $740.75 | |
| 85730 | <1% | 691 | $731.04 | |
| 88142 | <1% | 565 | $713.93 | |
| 80074 | <1% | 69 | $689.33 | |
| 86140 | <1% | 760 | $671.96 | |
| 86900 | <1% | 1,122 | $667.87 | |
| 82746 | <1% | 244 | $638.04 | |
| 72100 | <1% | 55 | $635.63 | |
| 82728 | <1% | 420 | $570.93 | |
| 83550 | <1% | 290 | $548.95 | |
| 85007 | <1% | 784 | $503.04 | |
| 81003 | <1% | 1,038 | $499.30 | |
| 84480 | <1% | 298 | $452.32 | |
| 83540 | <1% | 449 | $435.18 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 66 | $424.23 |
| 87486 | <1% | 65 | $423.95 | |
| 87581 | <1% | 65 | $379.38 | |
| 82951 | <1% | 54 | $295.88 | |
| 87077 | <1% | 220 | $244.91 | |
| 84550 | <1% | 250 | $228.57 | |
| 73502 | <1% | 17 | $222.95 | |
| 82570 | <1% | 230 | $199.23 | |
| 83970 | <1% | 13 | $167.80 | |
| 84156 | <1% | 305 | $159.37 | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 22 | $123.05 |
| 84436 | <1% | 115 | $118.53 | |
| 86431 | <1% | 50 | $75.13 | |
| 87350 | <1% | 12 | $75.00 | |
| 83615 | <1% | 49 | $66.40 | |
| 84484 | <1% | 33 | $51.24 | |
| 86696 | <1% | 17 | $39.86 | |
| 82952 | <1% | 54 | $33.78 | |
| 82247 | <1% | 15 | $24.97 | |
| 86200 | <1% | 12 | $21.38 | |
| 84100 | <1% | 15 | $16.13 | |
| J2680 | Injection, fluphenazine decanoate, up to 25 mg | 0% | 27 | $0.00 |
| 85041 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOLE, ROBIN (CREDENTIALING SPECIALIST)
| Provider | Location | Paid |
|---|---|---|
| Central Florida Speech & Hearing Center | Lakeland, FL | $84K |
| Central Florida Speech & Hearing Center | Lakeland, FL | $3K |
| Lewis Cole DMD PC | Northport, AL | $422.40 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.